Laurion Capital Management LP Galapagos Nv Transaction History

Laurion Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$185.52 - $231.25 $374,379 - $466,662	-2,018 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$143.0 - $274.03 $288,574 - $552,992	2,018 New	2,018 $395,000
Q3 2019 Nov 13, 2019	SELL	$130.44 - $187.64 $496,454 - $714,157	-3,806 Closed	0 $0
Q2 2019 Aug 13, 2019	BUY	$111.45 - $128.93 $424,178 - $490,707	3,806 New	3,806 $491,000
Q1 2019 May 08, 2019	SELL	$89.61 - $117.78 $3.06 Million - $4.02 Million	-34,168 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$87.81 - $110.65 $12.5 Million - $15.7 Million	-142,308 Reduced 80.64%	34,168 $3.14 Million
Q3 2018 Nov 13, 2018	BUY	$90.63 - $120.22 $16 Million - $21.2 Million	176,476 New	176,476 $19.8 Million

12.3M

69.1K

42.7K

Ticker GLPG
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,835,500
Market Cap $1.9B
Description
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative coliti...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.